Gen AI ROI Falls Short, But Belief Persists
A new Deloitte survey reveals that although returns on generative AI are lacking, enthusiasm remains high. CIOs face pressing challenges in scaling up deployment effectively.
Read More
Year: 2025
IPA Develops AI-Designed GLP-1 Therapies
ImmunoPrecise Antibodies utilizes AI to create novel GLP-1 therapies aimed at enhancing diabetes treatment efficacy, safety, and patient satisfaction.
Read More
Microsoft and OpenAI Strengthen AI Partnership
Microsoft and OpenAI extend their strategic partnership to enhance AI development through IP rights, revenue sharing, and increased investment, solidifying Azure’s exclusivity for OpenAI APIs.
Read More